// App-Quantinova.ai

WP281 2016 ASA : Plasma Kallikrein Inhibition Reduces Tissue Plasminogen Activator-induced Stroke Damage and Hemorrhage Transformation

Researchers

Presenter

  • Allen C. Clermont

Principal Investigators

  • Edward P. Feener

Medical Centers

  • Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Intracerebral hemorrhage

  • Ischemic stroke

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved